For all the talk from economists that Australia is immune or near immune to the US-China trade war and President Donald Trump’s tariffs, the experience inside Australia’s boardrooms is very different.
Just like our financial markets, when the US sneezes, our boards and their management teams and investors all go cold. Uncertainty takes over, expansion or re-investment plans are delayed, and boards batten down the hatches and await more bullish times.